Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

Rhea-AI Summary

Regeneron Pharmaceuticals announced it will release its Q2 2024 financial and operating results on August 1, 2024, before U.S. markets open. The company will hold a conference call and webcast at 8:30 AM ET on the same day. Investors can access the webcast via Regeneron's investor relations page. For telephone participation, pre-registration is required. A replay and transcript of the call will be available on the company's website for a minimum of 30 days.

Positive

• Upcoming release of Q2 2024 financial and operating results on August 1, 2024.
• Conference call and webcast scheduled, providing transparency and investor engagement.

Negative

• None.

TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite^®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center^® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com

Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com

FAQ

When will Regeneron report its Q2 2024 financial results?

Regeneron will report its Q2 2024 financial results on August 1, 2024.

How can I access Regeneron's Q2 2024 financial results webcast?

You can access the webcast on Regeneron's 'Investors and Media' page on their website.

Can I listen to Regeneron's Q2 2024 financial results via telephone?

Yes, but you must pre-register to receive the dial-in number and a unique passcode.

Will Regeneron provide a replay of the Q2 2024 financial results conference call?

Yes, a replay and transcript will be available on Regeneron's website for at least 30 days.